Add Ezetimibe Immediately
This patient requires the addition of ezetimibe to his current regimen of statin plus evolocumab (Repatha), as his LDL remains at 4 mmol/L (154 mg/dL), which is far above target for someone already on PCSK9 inhibitor therapy.
Why This Patient Needs Ezetimibe Now
The standard treatment algorithm for very high-risk patients follows a stepwise approach: maximize statin → add ezetimibe → add PCSK9 inhibitor 1. This patient appears to have skipped ezetimibe and gone directly to the PCSK9 inhibitor, which is not the recommended sequence.
Key guideline thresholds that apply here:
- Canadian guidelines: PCSK9 inhibitors should only be added when LDL remains ≥2.6 mmol/L (100 mg/dL) despite maximally tolerated statin PLUS ezetimibe 1
- ESC/EAS guidelines: Combination with ezetimibe is recommended before escalating to PCSK9 inhibitors 1
- NICE guidelines: PCSK9 inhibitors are approved when patients fail to meet targets despite statin and ezetimibe therapy 1
The Problem: Incomplete Triple Therapy
At 69 years old with an LDL of 4 mmol/L on statin + Repatha, this patient is experiencing inadequate lipid control. The most likely explanations are:
- Ezetimibe was never added (most common scenario)
- Statin dose is not maximized
- Adherence issues with Repatha
- Severe familial hypercholesterolemia requiring dose escalation
Immediate Action Steps
First: Add ezetimibe 10 mg daily 1. This will provide an additional 15-25% LDL reduction and is the missing component of guideline-concordant triple therapy.
Second: Verify the following:
- Is the patient on a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)?
- Is Repatha being administered correctly at 140 mg every 2 weeks or 420 mg monthly? 2
- Check LDL 4 weeks after adding ezetimibe 2
Third: If LDL remains >2.6 mmol/L after 12 weeks on maximal triple therapy:
- Consider increasing Repatha to 420 mg every 2 weeks (for homozygous FH or severe cases) 2
- Reassess for secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, medications)
- Consider referral to lipid specialist
Target LDL for This Patient
For a 69-year-old on PCSK9 inhibitor therapy, the presumption is very high cardiovascular risk (established ASCVD or severe FH):
- ESC/EAS target: <1.4 mmol/L (55 mg/dL) for very high-risk patients 1
- Canadian target: <1.8 mmol/L (70 mg/dL) for very high-risk patients 1
His current LDL of 4 mmol/L is nearly 3 times the upper target threshold.
Critical Pitfall to Avoid
Do not assume the PCSK9 inhibitor is "failing" and discontinue it. The issue is incomplete implementation of the treatment ladder. PCSK9 inhibitors reduce LDL by approximately 60% 3, but if ezetimibe was never added, you're missing a crucial 15-25% reduction that should have been achieved first.
Expected Outcome
With proper triple therapy (high-intensity statin + ezetimibe + Repatha 140 mg Q2 weeks), expect:
- Combined LDL reduction of 70-80% from baseline
- Most patients achieve LDL <1.4 mmol/L 1
- Reassess at 4 weeks, with full evaluation at 12 weeks 2